Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
Plasma GFAP voorspelt veranderingen in MRI-markers bij cSVD
mei 2026 | Neuro-vasculair